Table 6.

Time in therapeutic range achieved under different models of anticoagulation management and with different testing frequencies.

Study
Predominant Model of Management
% Time in Therapeutic Range*
% Above Range
% Below Range
Frequency of Monitoring§
Garabedian, 1985148   UC   64   —   —   —  
Gottlieb, 1994170  UC 50 30 20 q 25 days§ 
Holm, 1999171   UC   63   8   29   —  
Beyth, 1997162   UC   33   16   51   —  
Horstkotte, 1998143  UC 59 — — q 19 days§ 
Sawicki, 1999165   UC   34   16   50   —  
Palaretti, 1996115   ACC   68   6   26   q 15 days§ 
Cannegeiter, 1995104  ACC 61 8 31 q 18.9 days§ 
Lundstrom, 1989172   ACC   92   —   —   —  
Garabedian, 1985148   ACC   86   —   —   —  
White, 1989160   ACC   75   —   —   
Ansell, 1995163  ACC 68 10 22 q 16 days§ 
Conte, 1986145   ACC   59   12   29   —  
Seabrook, 1990146   ACC   86   7   7   once a month  
White, 1989160   PST   93   —   —   —  
Beyth, 1997162   PST   56   14   30   —  
Ansell, 1995163   PSM   89   5   6   q 13.8 days§ 
Horstkotte, 1998143  PSM 92 — — q 4 days§ 
Sawicki, 1999165   PSM   57   10   33   —  
AFASAK, 1989140   RCT   73   0.6   26   —  
BAATF, 1990138   RCT   83   9   8   q 3 weeks  
SPAF I, 1991173   RCT   71   5   23   at least once a month  
SPAF II, 1994174   RCT   74   5   21   at least once a month  
SPAF III, 1996   RCT   61   14   25   at least once a month  
SPINAF, 1992132   RCT   56   15   29   monthly  
CAFA, 1991139   RCT   44   16   40   q 3 weeks  
AFASAK II, 1999175   RCT   73   9   18   not > q 4 weeks  
EAFT, 1993105   RCT   59   9   32   q 5 weeks  
Hellemans, 1999176   RCT   48   24   28   q 2-6 weeks  
Hutten, 1999177   RCT   61   —   —   —  
Abbreviations: UC, usual care; ACC, anticoagulation clinic; PST, patient self-testing; PSM, patient self-management; RCT, randomized controlled trial  
Study
Predominant Model of Management
% Time in Therapeutic Range*
% Above Range
% Below Range
Frequency of Monitoring§
Garabedian, 1985148   UC   64   —   —   —  
Gottlieb, 1994170  UC 50 30 20 q 25 days§ 
Holm, 1999171   UC   63   8   29   —  
Beyth, 1997162   UC   33   16   51   —  
Horstkotte, 1998143  UC 59 — — q 19 days§ 
Sawicki, 1999165   UC   34   16   50   —  
Palaretti, 1996115   ACC   68   6   26   q 15 days§ 
Cannegeiter, 1995104  ACC 61 8 31 q 18.9 days§ 
Lundstrom, 1989172   ACC   92   —   —   —  
Garabedian, 1985148   ACC   86   —   —   —  
White, 1989160   ACC   75   —   —   
Ansell, 1995163  ACC 68 10 22 q 16 days§ 
Conte, 1986145   ACC   59   12   29   —  
Seabrook, 1990146   ACC   86   7   7   once a month  
White, 1989160   PST   93   —   —   —  
Beyth, 1997162   PST   56   14   30   —  
Ansell, 1995163   PSM   89   5   6   q 13.8 days§ 
Horstkotte, 1998143  PSM 92 — — q 4 days§ 
Sawicki, 1999165   PSM   57   10   33   —  
AFASAK, 1989140   RCT   73   0.6   26   —  
BAATF, 1990138   RCT   83   9   8   q 3 weeks  
SPAF I, 1991173   RCT   71   5   23   at least once a month  
SPAF II, 1994174   RCT   74   5   21   at least once a month  
SPAF III, 1996   RCT   61   14   25   at least once a month  
SPINAF, 1992132   RCT   56   15   29   monthly  
CAFA, 1991139   RCT   44   16   40   q 3 weeks  
AFASAK II, 1999175   RCT   73   9   18   not > q 4 weeks  
EAFT, 1993105   RCT   59   9   32   q 5 weeks  
Hellemans, 1999176   RCT   48   24   28   q 2-6 weeks  
Hutten, 1999177   RCT   61   —   —   —  
Abbreviations: UC, usual care; ACC, anticoagulation clinic; PST, patient self-testing; PSM, patient self-management; RCT, randomized controlled trial  
*

Time in range represents mean or median percent of PTs or days in range.

§

Those studies that documented the achieved frequency of monitoring as opposed to the stated goal for monitoring interval are in bold.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal